Patents Examined by Yunsoo Kim
  • Method for production of antibody
    Patent number: 11136375
    Abstract: The present invention provides a method of producing a recombinant antibody efficiently and at low cost. Disclosed is a method of producing an antibody or a fragment thereof, comprising allowing a cell to produce the antibody or the fragment, wherein the cell contains a larger number of copies of an exogenous DNA encoding the light chain or a fragment thereof of the antibody than the number of copies contained in the cell of an exogenous DNA encoding the heavy chain or a fragment thereof of the antibody. The present invention also provides a recombinant vector comprising one copy of a DNA encoding the heavy chain or a fragment thereof of an antibody and two or more copies of a DNA encoding the light chain or a fragment thereof of the antibody; and a transformant.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 5, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshiki Yamada, Tatsuya Kiyasu, Kazuyuki Tabata, Akihiro Kuzumaki, Mai Yamashiro
  • Method for preparing composition comprising a cationic oil-in-water emulsion
    Patent number: 11135287
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 5, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Luis Brito, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
    Patent number: 11110168
    Abstract: The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: September 7, 2021
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Zhen Gu, Chao Wang, Yanqi Ye
  • Aluminum compounds for use in therapeutics and vaccines
    Patent number: 11110170
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: September 7, 2021
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber
  • Immunogenic composition for the treatment of cancer and methods of preparing the same
    Patent number: 11103466
    Abstract: The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition. Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including; an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 31, 2021
    Assignee: JACINTO CONVIT WORLD ORGANIZATION INC.
    Inventor: Jacinto Convit
  • Compositions and methods for stabilizing protein-containing formulations
    Patent number: 11103584
    Abstract: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 31, 2021
    Assignee: GENENTECH, INC.
    Inventors: Osigwe Esue, Vikas K. Sharma
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 11098127
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Phosphoserine containing compositions for immune tolerance induction
    Patent number: 11083782
    Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 10, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Sathy Balu-Iyer, Richard Bankert, Radha Ramakrishnan, Robert Dingman, Vandana Iyer, Jennifer Schneider, Fiona Yau Glassman, Nhan Hanh Nguyen
  • Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response
    Patent number: 11077184
    Abstract: The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: August 3, 2021
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Lisa Diana MacDonald, Genevieve Mary Weir, Leeladhar Sammatur, Kendall Sharp
  • Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
    Patent number: 11058769
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
  • Immunity-inducing agent
    Patent number: 11045534
    Abstract: The present application relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MCEMP1 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 29, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takayuki Fujita, Fumiyoshi Okano
  • Antibody composition and buffer system therefor
    Patent number: 11046753
    Abstract: A method for conjugating an isolated antibody to a label or derivatisation reagent, which method comprises contacting the antibody with an activated label or activated derivatisation reagent, or contacting the antibody with the label or derivatisation reagent in the presence of an antibody conjugation reagent, in a buffer system which comprises a monocarboxylic acid buffer compound other than glycine, bearing an amine substituent at the alpha or beta position.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: June 29, 2021
    Assignee: INNOVA BIOSCIENCES LTD.
    Inventors: Nicolas Steven Gee, Bianca Fusetti
  • Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
    Patent number: 11028156
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 8, 2021
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Carrier-antibody compositions and methods of making and using the same
    Patent number: 10993912
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Carrier-antibody compositions and methods of making and using the same
    Patent number: 10993911
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Conjugate vaccine targeting a disease-causing biological protein
    Patent number: 10980876
    Abstract: The present invention provides a vaccine containing a complex of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and an epitope of a disease-causing biological protein such as DPP4, IL-17A, IgE, S100A9 or PCSK9, which vaccine uses a less antigenic carrier protein and is capable of inducing antibody production to serve as an effective vaccine.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: April 20, 2021
    Assignees: OSAKA UNIVERSITY, FUNPEP CO., LTD.
    Inventors: Hironori Nakagami, Ryuichi Morishita, Akiko Tenma
  • Carrier-antibody compositions and methods of making and using the same
    Patent number: 10966923
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: April 6, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Immunoglobulin formulation and method of preparation thereof
    Patent number: 10954303
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOGEN MA INC.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Carbohydrate content of CTLA4 molecules
    Patent number: 10941189
    Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: March 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
  • Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
    Patent number: 10933129
    Abstract: Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 2, 2021
    Assignee: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Conlin O'Neil, Petr Ilyinskii